

Mark E Schnute

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8653198/publications.pdf>

Version: 2024-02-01

12
papers

719
citations

759233

12
h-index

1199594

12
g-index

13
all docs

13
docs citations

13
times ranked

1214
citing authors

#	ARTICLE	IF	CITATIONS
1	Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. <i>Biochemical Journal</i> , 2012, 444, 79-88.	3.7	238
2	Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis. <i>Journal of Immunology</i> , 2013, 191, 4540-4550.	0.8	98
3	Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis: Confirmation by multivariate analysis that modulation of type ii collagen and aggrecan degradation peptides parallels pathologic changes. <i>Arthritis and Rheumatism</i> , 2010, 62, 3006-3015.	6.7	58
4	4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as Non-Nucleoside Inhibitors of Human Cytomegalovirus and Related Herpesvirus Polymerases. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 5794-5804.	6.4	55
5	Structural and Inhibition Analysis Reveals the Mechanism of Selectivity of a Series of Aggrecanase Inhibitors. <i>Journal of Biological Chemistry</i> , 2009, 284, 24185-24191.	3.4	52
6	Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 576-580.	2.2	44
7	2-Aryl-2-hydroxyethylamine substituted 4-oxo-4,7-dihydrothieno[2,3-b]pyridines as broad-spectrum inhibitors of human herpesvirus polymerases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 3349-3353.	2.2	42
8	Discovery of a Potent and Selective Sphingosine Kinase 1 Inhibitor through the Molecular Combination of Chemotype-Distinct Screening Hits. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2562-2572.	6.4	39
9	Discovery of (4-Fluoro-3-methoxybenzyl)-6-(2-((S)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2H-tetrazole as a Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 313-327.	6.4	27
10	Discovery of 3-Cyano-N-(3-(1-isobutryl)piperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10415-10439.	6.4	26
11	Synthesis of 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamides with broad-spectrum human herpesvirus polymerase inhibition. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 3856-3859.	2.2	22
12	Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 80-85.	2.8	18